| Literature DB >> 34791363 |
Tae Hoon Oh1,2, Jong Hyun Baeck1, Seung Ryeol Lee1, Dong Soo Park1, Young Dong Yu1.
Abstract
INTRODUCTION: This study evaluated the epidemiological factors of sexually transmitted infections (STIs) among South Korean troops including the prevalence, therapeutic methods, and sexual risk behaviors.Entities:
Year: 2021 PMID: 34791363 PMCID: PMC8690001 DOI: 10.1093/milmed/usab479
Source DB: PubMed Journal: Mil Med ISSN: 0026-4075 Impact factor: 1.437
Baseline Characteristics of Soldiers Diagnosed with STIs (n = 138)
| Parameters | Values |
|---|---|
| Age (years), mean ± SD | 21.2 ± 0.9 |
| Gender, | |
| Male | 138 (100.0) |
| Female | 0 (0.0) |
| Military rank, | |
| Private first class | 16 (11.6) |
| Private | 33 (23.9) |
| Corporal | 62 (37.7) |
| Sergeant | 37 (26.8) |
| Service branch | |
| Army | 109 (78.9) |
| Navy | 2 (1.5) |
| Air Force | 27 (19.6) |
| Period in the military service (months), mean (range) | 15.7 (4.0-17.3) |
| Education level, | |
| High school graduate | 93 (67.4) |
| College education (time-off for military service) | 45 (32.6) |
| Marital status | |
| Single, never married | 138 (100.0) |
| Married | 0 (0.0) |
| Divorced | 0 (0.0) |
| Abnormal urine analysis results, | |
| Pyuria | 95 (68.8) |
| Microscopic hematuria | 31 (22.5) |
| Bacteriuria | 79 (57.2) |
| Previous history of STIs | 24 (17.4) |
| Underlying disease | |
| Congenital urogenital anomaly | 0 (0.0) |
| Hypertension | 0 (0.0) |
| Diabetes mellitus | 0 (0.0) |
STIs; sexually transmitted infections.
STIs and Related Clinical Symptoms (n = 138)
| Patients | Treatment methods | |||
|---|---|---|---|---|
| STI type | Treatment period |
| % | |
| Neisseria gonorrheae | Overall | 41 | 29.7 | |
| Pre-COVID-19 | 31/41 | 75.6 | Intravenous ceftriaxone 1 g, once + oral azithromycin 1 g, once | |
| COVID-19 | 10/41 | 24.4 | ||
| Treponema pallidum | Overall | 29 | 21.0 | |
| Pre-COVID-19 | 21/29 | 72.4 | Intramuscular benzathine penicillin G 2.4 million IU, once | |
| COVID-19 | 8/29 | 27.6 | ||
| Trichomonas vaginalis | Overall | 17 | 12.3 | |
| Pre-COVID-19 | 10/17 | 58.8 | Oral metronidazole 2 g, once | |
| COVID-19 | 7/17 | 41.1 | ||
| Chlamydia trachomatis | Overall | 15 | 10.9 | |
| Pre-COVID-19 | 11/15 | 73.3 | Oral azithromycin 1 g, once | |
| COVID-19 | 4/15 | 26.7 | ||
| HPV (condyloma) | Overall | 15 | 10.9 | |
| Pre-COVID-19 | 10/15 | 66.7 | Mass excision and CO2 LASER ablation | |
| COVID-19 | 5/15 | 33.3 | ||
| Ureaplasma urealyticum | Overall | 10 | 7.2 | |
| Pre-COVID-19 | 7/10 | 70.0 | Oral doxycycline 100 mg, 2 times/day, for 7 days | |
| COVID-19 | 3/10 | 30.0 | ||
| HSV (type 1 and 2) | Overall | 6 | 4.3 | Oral famciclovir 250 mg, 3 times/day, for 7 days + 5% acyclovir ointment, 5 times/day, for 7 days |
| Pre-COVID-19 | 4/6 | 66.7 | ||
| COVID-19 | 2/6 | 33.3 | ||
| Mycoplasma genitalium | Overall | 5 | 3.6 | |
| Pre-COVID-19 | 4/5 | 80.0 | Oral doxycycline 100 mg, 2 times/day, for 7 days | |
| COVID-19 | 1/5 | 20.0 | ||
| Ureaplasma parvum | Overall | 0 | 0.0 | N/A |
| HIV | Overall | 0 | 0.0 | N/A |
| Candida albicans | Overall | 0 | 0.0 | N/A |
| Scabies (pubic lice) | Overall | 0 | 0.0 | N/A |
| Clinical symptoms | ||||
| Urethral discharge | 68 | 49.2 | N/A | |
| Genital wartz | 15 | 10.9 | ||
| Rash or other skin lesions in genitalia | 33 | 23.9 | ||
| Pain in genitalia | 73 | 52.9 | ||
| Pruritis in genitalia or peri-genital area | 12 | 8.7 | ||
| Voiding urethral pain | 98 | 71.0 | ||
| Fever and myalgia | 3 | 2.2 | ||
Abbreviations: HIV: human immunodeficiency virus; HPV: human papillomavirus; HSV: herpes simplex virus; STIs: sexually transmitted infections.
Antibiotic Sensitivity for STI Pathogens
| Pathogens, | |||
|---|---|---|---|
| Antibiotics | Neisseria gonorrheae | Mycoplasma genitalium | Ureaplasma urealyticum |
| Azithromycin | |||
| Sensitive | 38 (92.7) | 2 (40.0) | 3 (30.0) |
| Intermediate | 1 (2.4) | 0 (0.0) | 1 (10.0) |
| Resistant | 1 (2.4) | 3 (60.0) | 6 (60.0) |
| Clarithromycin | N/A | ||
| Sensitive | 2 (40.0) | 1 (10.0) | |
| Intermediate | 1 (20.0) | 1 (10.0) | |
| Resistant | 2 (40.0) | 8 (80.0) | |
| Josamycin | N/A | ||
| Sensitive | 5 (100.0) | 10 (100.0) | |
| Intermediate | 0 (0.0) | 0 (0.0) | |
| Resistant | 0 (0.0) | 0 (0.0) | |
| Spectinomycin | N/A | N/A | |
| Sensitive | 35 (85.3) | ||
| Intermediate | 4 (9.8) | ||
| Resistant | 2 (4.9) | ||
| Pristinamycin | N/A | ||
| Sensitive | 5 (100.0) | 10 (100.0) | |
| Intermediate | 0 (0.0) | 0 (0.0) | |
| Resistant | 0 (0.0) | 0 (0.0) | |
| Erythromycin | N/A | ||
| Sensitive | 2 (40.0) | 0 (0.0) | |
| Intermediate | 0 (0.0) | 3 (30.0) | |
| Resistant | 3 (60.0) | 7 (70.0) | |
| Tetracycline | N/A | ||
| Sensitive | 4 (80.0) | 9 (90.0) | |
| Intermediate | 1 (20.0) | 0 (0.0) | |
| Resistant | 0 (0.0) | 1 (10.0) | |
| Doxycycline | |||
| Sensitive | 0 (0.0) | 5 (100.0) | 10 (100.0) |
| Intermediate | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Resistant | 41 (100.0) | 0 (0.0) | 0 (0.0) |
| Ofloxacin | |||
| Sensitive | 0 (0.0) | 1 (20.0) | 2 (20.0) |
| Intermediate | 0 (0.0) | 0 (0.0) | 1 (10.0) |
| Resistant | 41 (100.0) | 4 (80.0) | 7 (70.0) |
| Ciprofloxacin | |||
| Sensitive | 0 (0.0) | 0 (0.0) | 2 (20.0) |
| Intermediate | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Resistant | 41 (100.0) | 5 (100.0) | 8 (80.0) |
| Ceftriaxone | N/A | N/A | |
| Sensitive | 41 (100.0) | ||
| Intermediate | 0 (0.0) | ||
| Resistant | 0 (0.0) | ||
Abbreviations: STIs: sexually transmitted infections; N/A: not applicable.
Sexual and Social Behavior Pattern (n = 138)
| Before propensity matching | After propensity matching | |||||
|---|---|---|---|---|---|---|
| Pre-COVID-19 | COVID-19 | Pre-COVID-19 | COVID-19 | |||
| Alcohol use, | ||||||
| 97 (91.5) | 30 (93.8) | .683 | 23 (88.5) | 24 (92.3) | .641 | |
| Alcohol use at the last sexual contact | 102 (96.2) | 30 (93.8) | .549 | 25 (96.2) | 24 (92.3) | .556 |
| Sexual risks, | ||||||
| Condom use at the last sex | 41 (38.7) | 11 (34.4) | .661 | 9(34.6) | 10(38.5) | .775 |
| Unwanted sexual contact (forced by others) | 0 (0.0) | 0 (0.0) | – | 0 (0.0) | 0 (0.0) | – |
| 23 (21.7) | 5 (15.6) | .456 | 6 (23.1) | 4 (15.4) | .486 | |
| Involved in sex after onset of STI-related symptoms | 3 (2.8) | 6 (18.8) |
| 1 (3.8) | 4 (15.4) | .162 |
| Partner type at the last sex, |
| .163 | ||||
| Spouse | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
| Regular, non-spouse | 95 (89.6) | 24 (75.0) | 23 (88.5) | 19 (73.1) | ||
| One-night stand, not a sex worker | 11 (10.4) | 8 (25.0) | 3 (11.5) | 7 (26.9) | ||
| Sex worker | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
| Engaged in group or homosexual activity, | 0 (0.0) | 0 (0.0) | N/A | 0 (0.0) | 0 (0.0) | N/A |
| Psychological distress (work- or personal life–related) | ||||||
| Suicide ideation | 2 (1.9) | 4 (12.5) |
| 2 (7.7) | 4 (15.4) | .390 |
| Suicide attempt | 0 (0.0) | 0 (0.0) | N/A | 0 (0.0) | 0 (0.0) | N/A |
Off-duty indicates staying overnight outside military base for ≥1 day.
Binge drinking is defined by consuming more than five standard drinks (1 standard drink = 350 cc/1 can of 5% beer) during each day of off-duty time.
Multiple sex partner: ≥2 sex partners.
P-values written in bold characters indicate statistically significant numbers.
N/A: not applicable.